ZIGVATA Trademark

Trademark Overview

On Thursday, September 3, 2020, a trademark application was filed for ZIGVATA with the United States Patent and Trademark Office. The USPTO has given the ZIGVATA trademark a serial number of 90156846. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 20, 2024. This trademark is owned by Pfizer Inc.. The ZIGVATA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of alopecia areata, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis
zigvata

General Information

Serial Number90156846
Word MarkZIGVATA
Filing DateThursday, September 3, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 16, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of alopecia areata, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 8, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, September 7, 2020NEW APPLICATION ENTERED
Thursday, October 8, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 7, 2021ASSIGNED TO EXAMINER
Friday, January 8, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 27, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 16, 2021PUBLISHED FOR OPPOSITION
Tuesday, February 16, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 28, 2021SOU EXTENSION 1 FILED
Tuesday, September 28, 2021SOU EXTENSION 1 GRANTED
Thursday, September 30, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 24, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 20, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, April 13, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 28, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, March 22, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, March 22, 2022SOU EXTENSION 2 FILED
Tuesday, March 22, 2022SOU EXTENSION 2 GRANTED
Tuesday, September 20, 2022SOU EXTENSION 3 FILED
Tuesday, September 20, 2022SOU EXTENSION 3 GRANTED
Thursday, September 22, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 28, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, March 29, 2023SOU EXTENSION 4 FILED
Wednesday, March 29, 2023SOU EXTENSION 4 GRANTED
Friday, March 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 15, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, March 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, March 28, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, March 29, 2023SOU TEAS EXTENSION RECEIVED
Thursday, September 21, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 21, 2023SOU EXTENSION 5 GRANTED
Friday, September 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 20, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, May 20, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Friday, September 15, 2023SOU EXTENSION 5 FILED

Related Keywords

zigvata preparations pharmaceutical disorders treatment disease arthritis anti infective medicated dermatological